Search Results < Yale Cancer Center

Yale Cancer Center

88 results

News
Updates in Head and Neck Cancer Treatment: Integrating Checkpoint Inhibitor Therapy to Improve Outcomes
Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.
Source: ReachMD
2 Aug 2021
News
Camrelizumab vs Placebo in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
In this phase III trial of first-line camrelizumab/gemcitabine/cisplatin versus gemcitabine/cisplatin in patients with metastatic or recurrent nasopharyngeal carcinoma, patients received four to six cycles of therapy followed by maintenance camrelizumab or placebo. The addition of camrelizumab significantly improved progression-free survival but caused higher rates of myelosuppression.
Source: Practice Update
7 Jul 2021
News
Barbara Burtness, MD on the Efficacy of Checkpoint Inhibitors in Head and Neck Cancer.
An unanswered question in the treatment of patients with head and neck cancer, specifically those with human papillomavirus (HPV)–associated oropharynx cancer and Epstein-Barr virus–associated nasopharynx cancer, is how immune checkpoint inhibitors fit into the management of curable-stage disease, Burtness says.
Source: OncLive
29 Jun 2021
News
Weekly Paclitaxel, Carboplatin, and Cetuximab as Induction Therapy for Metastatic or Relapsed Head and Neck Cancer
Dr. Burtness: Our group at Yale undertook a retrospective analysis to look at a regimen of weekly carboplatin, paclitaxel and cetuximab, which has been studied both in ECOG and MD Anderson, and is I think pretty commonly used in practice but has not been included as a control or an experimental arm in any of the large randomized trials, which have changed practice in head and neck cancer in recent years. One of the reasons that this regimen is appealing is it's more tolerable to people with renal injury, frailty, or advanced age. And we were interested in seeing what we could learn about its activity and tolerability in the patients we had treated at Yale, including those who were elderly or frail.
Source: Practice Update
24 Jun 2021
News
Outcomes for Patients With Locally Advanced Head and Neck Cancer Receiving Neoadjuvant Pembrolizumab
One of the interesting questions that can be posed when you look at this trial design is what is the advantage of giving neoadjuvant pembrolizumab in a group of patients where you know that you're going to be taking the patient to surgery.
Source: Practice Update
24 Jun 2021
News
Smilow Shares Greenwich: Head and Neck Cancers
On April 20, 2021, Smilow Shares in Greenwich presented a talk focused on Head and Neck Cancers.
21 Apr 2021
News
Head and Neck Cancer: Five Things You Need to Know
April is Head and Neck Cancer Awareness Month. Barbara Burtness, MD, Professor of Medicine (Medical Oncology) and the Disease Aligned Research Team Leader of the Head and Neck Cancers program at Yale Cancer Center, said it’s a good time to highlight warning signs, screening and prevention for this potentially deadly disease.
6 Apr 2021
News
HPV Is the Most Common STI in the US—but Does It Go Away on Its Own? Here's How Doctors Explain It
HPV (human papillomavirus) is the most common sexually transmitted infection in the United States, according to the Centers for Disease Control and Prevention (CDC). How common? More than 79 million people have it right now. And experts estimate that about 14 million people get infected every year.
Source: Parade
19 Mar 2021
News
Head & Neck Cancers Multidisciplinary Clinic at Smilow Cancer Hospital Care Center in Trumbull
The Head & Neck Cancers Multidisciplinary Clinic at Smilow Cancer Hospital is now available at the Park Avenue Medical Center on Mondays.
10 Feb 2021
News
Clarence T. Sasaki, MD '66, Emeritus Professor of Surgery (Otolaryngology), Dies
Sasaki was an exceptional surgeon-scientist, educator, and leader, whose generosity of knowledge and mentorship made a lasting impact on our department, our institution, and on the broader otolaryngology community.
8 Feb 2021
News
In Memoriam: Clarence T. Sasaki, MD 1941-2021
Clarence T. Sasaki MD, Charles W. Ohse Professor Emeritus of Surgery at the Yale School of Medicine, died peacefully on February 4, 2021. His prominent career is distinguished by his life-long passion for the academic mission, and as a champion of surgical leadership at Yale. He was the longest serving Chief of Otolaryngology, serving more than 30 years, between 1981 and 2012.
5 Feb 2021
News
Clarence T. Sasaki, MD Announces Clinical Retirement
Clarence T. Sasaki, MD, Charles W. Ohse Professor of Surgery, has retired from his clinical practice after over half of a century at the Yale School of Medicine.
3 Feb 2021
News
Head and Neck Surgeons Join Smilow Cancer Hospital
Head and Neck Surgeons Dr. Ronald Walker and Dr. Avanti Verma join Smilow Cancer Hospital.
29 Jan 2021
News
Video: Dr. Aarti Bhatia Discusses Throat Cancer
Dr. Aarti Bhatia talks to WFSB News 8 about throat cancer risks.
Source: WFSB News 8
7 Oct 2020
News
Yale Cancer Center Awarded NIH SPORE for Head and Neck Cancer Research
Yale Cancer Center researchers were awarded a five-year, $11.7 million grant from the National Institutes of Health to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence (SPORE).
Source: OncLive
1 Oct 2020
News
Yale Cancer Center Awarded NIH SPORE for Head and Neck Cancer Research
Yale Cancer Center researchers were awarded a five-year, $11.7 million grant from the National Institutes of Health to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence .
24 Sep 2020
News
The Blavatnik Fund for Innovation at Yale Awards $2.6 Million For Faculty Research
Awards include specific funding to support COVID-19 clinical trial
Source: Office of Cooperative Research
21 Jul 2020
News
Barbara Burtness Discusses Data Presented at ASCO 2020 Virtual Meeting
Watch Barbara Burtness discuss data presented at ASCO 2020 virtual meeting.
Source: Video Journal of Oncology
10 Jul 2020
News
Deintensification of Treatment in HPV-Associated Cancers Holds Promise, But With Caveats
De-escalating therapy has the potential to dramatically reshape the treatment of patients with HPV-associated oropharyngeal cancers, but only if a number of key trials come back with positive long-term data.
Source: Targeted Oncology
17 May 2020
News
Telemedicine Best Practices
According to Douglas M. Hildrew, MD, Chair of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) Telemedicine Committee and Assistant Professor of Surgery at the Yale School of Medicine, Division of Otolaryngology–Head & Neck Surgery, “On a very basic level, telemedicine involves using electronic communication strategies to provide clinical services and/or patient care remotely.
Source: ENT health
13 May 2020